SCHEMBL30885239

SCHEMBL30885239

CN(C)CCCNC(=O)c1cccc(-c2ccc3ccnc(N)c3c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHUK O15111 2/20 0.56
INSR P06213 2/20 0.56
MAPK8 P45983 2/20 0.56
CAMKK2 Q96RR4 2/20 0.56
FYN P06241 4/20 0.54
PRKD3 O94806 1/20 0.53
PRKD1 Q15139 1/20 0.53
PRKD2 Q9BZL6 1/20 0.53
MAP4K4 O95819 1/20 0.52
METAP2 P50579 1/20 0.49
KDM4E B2RXH2 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
TET3 O43151 1/20 0.48
TET2 Q6N021 1/20 0.48
TET1 Q8NFU7 1/20 0.48
PDE4B Q07343 1/20 0.46
PDE1A P54750 1/20 0.45
PDE1B Q01064 1/20 0.45
PDE4D Q08499 1/20 0.45
PDE7A Q13946 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27201568 1.00 CHUK (0.56) CHUKINSRMAPK8CAMKK2FYN
SCHEMBL27201382 0.85 MAP4K4 (0.66) CHUKINSRMAPK8CAMKK2FYN
SCHEMBL30885324 0.85 MAP4K4 (0.66) CHUKINSRMAPK8CAMKK2FYN
SCHEMBL27201337 0.84 CHUK (0.49) CHUKINSRMAPK8CAMKK2FYN
SCHEMBL30834184 0.82 CHUK (0.46) CHUKINSRMAPK8CAMKK2FYN
SCHEMBL27201391 0.82 CHUK (0.46) CHUKINSRMAPK8CAMKK2FYN
SCHEMBL30885290 0.78 PRKD3 (0.45) CHUKINSRMAPK8CAMKK2PRKD3
SCHEMBL27201439 0.78 PRKD3 (0.45) CHUKINSRMAPK8CAMKK2PRKD3
SCHEMBL24061104 0.77 FYN (0.59) CHUKINSRMAPK8CAMKK2FYN
SCHEMBL30885217 0.77 MAP4K4 (0.50) PRKD3PRKD1PRKD2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP CHUK 131/4885INSR 327/4885MAPK8 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.